6K: Purple Biotech Announces Initiation of Part 2 of Ongoing Phase 1/2 Clinical Trial Evaluating NT219 for Treatment of Multiple Cancers Supporting Po false
פרפל ביוטק בע"מ 2 380
PURPLE BIOTECH LTD
Corporation no: 520031238 13936
Israel Securities Authority   Tel Aviv Stock Exchange   C002 ( Public )   Reported via MAGNA: 06/12/2021
  www.isa.gov.il     www.tase.co.il       Reference: 2021-02-106690 Time of broadcast: 14:33 14:33
Immediate Report
Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000


The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on

ea151775-6k_purplebiotechEDGAR1_Bannerless_isa.pdf
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
       
Stock Exchange/Market: NASDAQ CM Date of revision of form structure: 19/10/2021
Address: Oppenheimer, Science Park 4 , Rehovot 7670104   , Israel Tel: 03-9333121 , 03-9311321 Fax: 03-5097196
E-mail address: ir@purple-biotech.com   Company site: www.kitovpharma.com

Previous names of reporting entity: KITOV PHARMA LTD, KITOV PHARMACEUTICALS HOLDINGS LTD, MAINROM LINE LOGISTICS LTD, ORLINE DEVELOPMENT AND INVESTMENT LTD, KADURY & HAI (MOLET) ASSETS & INVESTMENTS LTD,

Name of the Signatory: Livneh Nir Position of Signatory in the reporting corporation: Vice President & General Counsel Name of Employer Company:
Address: Oppenheimer 4 , Rehovot 7670104 Telephone: 050-5611024 Facsimile: 03-5097196 E-mail: nirl@purple-biotech.com 1
Israel